K. Wennerberg

Synthetic lethal interaction between WEE1 and PKMYT1 is a target for multiple low dose treatment of high-grade serous ovarian carcinoma

This study shows that combining low-dose WEE1 and PKMYT1 inhibition synergistically kills ovarian cancer cells by increasing genomic instability and inflammation, and is well-tolerated in mice.

A synthetic lethal dependency on casein kinase 2 in response to replication-perturbing drugs in RB1-deficient ovarian and breast cancer cells

This study identifies CK2 inhibition as a sensitizing strategy for RB1-deficient ovarian and breast cancer cells to replication-perturbing drugs, showing enhanced efficacy when combined with existing therapies.

Pharmacological PP2A reactivation overcomes multikinase inhibitor tolerance across brain tumor cell models

This study identifies a triplet therapy combining AKT, PDK1-4 inhibition, and PP2A reactivation that effectively eradicates brain tumor models by overcoming kinase inhibitor tolerance through combinatorial effects on signaling rewiring, OXPHOS, and apoptosis.

A platform for efficient establishment, expansion and drug response profiling of high-grade serous ovarian cancer organoids

This paper describes a method to generate and expand high-grade serous ovarian cancer organoids with improved success rates and reports their drug response correlation with clinical outcomes.

Development of Actionable Targets of Multi-kinase Inhibitors (AToMI) screening platform to dissect kinase targets of staurosporines in glioblastoma cells

The paper develops a platform to identify kinase targets of multi-kinase inhibitors in glioblastoma cells and finds AKT, PDK1, and PDK4 as targets of staurosporine derivatives that synergize with PP2A reactivation.

PI3Kβ inhibition restores ALK inhibitor sensitivity in ALK-rearranged lung cancer

The paper identifies PI3Kβ as a mediator of resistance to ALK inhibitors in ALK-rearranged lung cancer and shows that combining ALK and PI3Kβ inhibitors overcomes resistance.

COMPARE, an ultra-fast and robust suite for multiparametric screening, identifies phenotypic drug responses in acute myeloid leukemia

CIP2A interacts with TopBP1 and is selectively essential for DNA damage-induced basal-like breast cancer tumorigenesis

This study identifies CIP2A as a subtype-specific driver of DNA damage-induced basal-like breast cancer, showing its role in checkpoint signaling and therapeutic vulnerability.

Functional diagnostics using fresh uncultured lung tumor cells to guide personalized treatments

This study uses fresh uncultured lung tumor cells to assess drug responses and guide personalized treatment, showing clinical benefit in a refractory cancer case.

Multi-modal meta-analysis of cancer cell line omics profiles identifies ECHDC1 as a novel breast tumor suppressor

The paper integrates multi-modal omics data from cancer cell lines to identify ECHDC1 as a novel breast tumor suppressor and discover synthetic lethal interactions.

Crowdsourced mapping of unexplored target space of kinase inhibitors

The paper benchmarks predictive models for kinase inhibitor potencies using crowdsourced data and identifies new compound-kinase interactions.

DNA barcode-guided lentiviral CRISPRa tool to trace and isolate individual clonal lineages in heterogeneous cancer cell populations

This paper introduces a DNA barcode-guided CRISPRa tool for tracing and isolating individual clonal lineages in cancer cell populations, enabling unbiased analysis of subclonal evolution.

Epigenetic inhibitors sensitize DLBCL cells to rituximab and doxorubicin

This study identifies epigenetic inhibitors that enhance the effectiveness of immunochemotherapy in DLBCL by disrupting DNA repair and cell cycle pathways.